Arcus Biosciences (RCUS) Tops Q4 EPS by 21c
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($0.89), $0.21 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $33 million versus the consensus estimate of $35.71 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Assumes T-Mobile (TMUS) at Equal Weight
- EU aviation agency tells airlines to avoid Iran, Iraq and Lebanon airspace
- Deutsche Bank secures Saudi Arabia regional headquarters licence
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
